The Luvmeebody Wellnessclub/Blogs/Articles

For several years, the conversation around a class of medications known as GLP-1 receptor agonists has centered on their significant impact on type 2 diabetes and weight management. These medications, which include semaglutide and liraglutide, work by mimicking a natural gut hormone that signals satiety to the brain and helps regulate blood sugar [4].

However, a recent, large-scale study has broadened this conversation dramatically, providing strong evidence that the benefits of these therapies may extend directly to cardiovascular health, independent of their effects on blood sugar. This development marks a pivotal moment in how we approach the treatment of obesity as a complex metabolic condition with far-reaching health consequences.

What the Research Shows

A landmark study, known as the SELECT trial, published in The New England Journal of Medicine, investigated the effects of semaglutide (at a 2.4 mg dose) on cardiovascular outcomes [1]. This large-scale, randomized, placebo-controlled clinical trial involved over 17,600 adults who had preexisting cardiovascular disease and overweight or obesity (a BMI of 27 or higher), but who did not have a diagnosis of diabetes [1]. This last point is crucial, as it isolated the medication’s effects from its glucose-lowering properties.

The results were significant. The study found that participants receiving semaglutide had a 20% lower risk of experiencing a major adverse cardiovascular event—defined as cardiovascular death, nonfatal heart attack (myocardial infarction), or nonfatal stroke—compared to those who received a placebo [1].

Based on these compelling findings, the U.S. Food and Drug Administration (FDA) expanded the approved use for Wegovy (the brand name for semaglutide 2.4 mg). In early 2024, the FDA approved it to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [2]. This was the first time a weight-loss medication has been approved for this specific protective cardiovascular indication.

Experts note that while weight loss itself contributes to better heart health, the benefits observed in the SELECT trial may not be due to weight reduction alone [3]. The leading theory is that GLP-1 agonists may also have direct positive effects on the cardiovascular system, such as reducing inflammation, improving blood vessel function, and lowering blood pressure, though more research is needed to confirm these mechanisms [3, 4].

What This Means for Everyday Wellness

This research and subsequent FDA approval reinforce a critical shift in medical understanding: viewing and treating obesity as a chronic disease, not simply a cosmetic issue. Excess weight is a major risk factor for serious health problems, including heart disease, stroke, and high blood pressure [5]. The ability to use a medication to directly target the risk of these events is a significant advancement.

This development underscores that the goal of managing weight is fundamentally about improving overall health and reducing the risk of disease. The cardiovascular benefits provide a powerful, data-driven reason for addressing obesity as a core component of preventative healthcare for certain individuals.

It is essential to remember that these are prescription medications intended for specific patient populations who meet the criteria for their use. A healthcare provider is the only one who can determine if a GLP-1 agonist is appropriate for an individual’s health needs. As with any medication, they are accompanied by potential side effects—most commonly gastrointestinal issues like nausea, vomiting, and diarrhea—and require medical supervision [4].

Ultimately, these medications are designed to be a tool within a comprehensive wellness plan that includes a balanced diet, regular physical activity, and other healthy lifestyle habits. They are not a replacement for these foundational pillars of health.

A Gentle Reminder

Your wellness journey is unique to you. New medical advancements offer powerful tools, but they are best navigated in partnership with a qualified healthcare professional who understands your personal health history and goals.

Sources and Resources

1. [1] NEJM. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023-11-11). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
2. [2] FDA. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults with Obesity or Overweight (2024-03-08). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-adults-obesity-or-overweight
3. [3] Harvard Health Publishing. Weight loss drug Wegovy approved to treat more than obesity (2024-05-01). https://www.health.harvard.edu/blog/weight-loss-drug-wegovy-approved-to-treat-more-than-obesity-202405013038
4. [4] Cleveland Clinic. GLP-1 Agonists (2023-11-20). https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
5. [5] CDC. Health Effects of Overweight & Obesity (2024-05-15). https://www.cdc.gov/healthyweight/effects/index.html

---

Educational disclaimer: This article is for general wellness education only. It is not medical advice and does not diagnose, treat, cure, or prevent any condition. It is not a substitute for consultation with a qualified healthcare professional. Always speak with your clinician before starting or changing any medication, supplement, or wellness routine, especially if you are pregnant, nursing, taking medication, or managing a health condition.

---

Explore more guided wellness at
The Luvmee Body Wellness Club.

---